ALNY vs SUPN · P/E 76, rev $1.29B vs rev $426.8M
Alnylam Pharmaceuticals Inc (ALNY) versus Supernus Pharmaceuticals Inc (SUPN) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Supernus Pharmaceuticals Inc (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported SUPN revenue for 2026-06-30 was $426.8M. Net income was -$60.7M. SUPN currently screens at market cap $2.53B.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. SUPN currently screens at market cap $2.53B.
Not investment advice. Open the ALNY and SUPN stock pages for the full models.
Not investment advice.